ASX:BOT Botanix Pharmaceuticals (BOT) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Botanix Pharmaceuticals Stock (ASX:BOT) 30 days 90 days 365 days Advanced Chart Get BOT alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolume1.63 million shsAverage VolumeN/AMarket Capitalization$912.82 millionP/E RatioN/ADividend Yield2.96%Price TargetN/AConsensus RatingN/A Company OverviewBotanix Pharmaceuticals Limited engages in the research and development of dermatology and antimicrobial products in Australia. The company engages in development of novel treatments for common skin diseases and infections. Its product pipeline includes Sofpironium Bromide, a drug in development for the treatment of primary axillary hyperhidrosis that has completed Phase 3 clinical programs; BTX 1503, a transdermal gel formulation for the treatment of serious acne in adults and teenagers that has completed Phase II clinical trials; BTX 1801, which has completed Phase IIb clinical trials for the treatment of staphylococcus aureus and methicillin resistant staphylococcus aureus; BTX 1702 that is in Phase II clinical trials for the treatment of papulopustular rosacea; and BTX 1204A for the treatment of atopic dermatitis. Botanix Pharmaceuticals Limited was incorporated in 1984 and is based in Leederville, Australia.Read More… Receive BOT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Botanix Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address BOT Stock News HeadlinesBotanix Pharmaceuticals Expands Market Presence with New Securities QuotationApril 24, 2025 | tipranks.comBotanix Pharmaceuticals Raises A$40 Million Through Share PlacementApril 24, 2025 | tipranks.comSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bill Gates has backed four companies in this space. The World Economic Forum calls it “the most exciting human discovery since fire.” Whitney Tilson believes this trend could mint a new class of wealthy investors—and he’s sharing one stock to watch now, for free.May 5, 2025 | Stansberry Research (Ad)Health Check: Trump says a pharma tax is in the offing – with no negotiationApril 15, 2025 | msn.comBotanix Pharmaceuticals Secures $40 Million to Boost Sofdra™ RolloutApril 14, 2025 | tipranks.comBotanix Pharmaceuticals Hosts Webinar on Sofdra Launch and Strategic UpdatesApril 14, 2025 | tipranks.comBotanix Pharmaceuticals taps investors for $40m; Euroz, E&P in towApril 14, 2025 | afr.com3 reasons to buy this surging ASX All Ords healthcare share todayApril 2, 2025 | msn.comSee More Headlines BOT Stock Analysis - Frequently Asked Questions How were Botanix Pharmaceuticals' earnings last quarter? Botanix Pharmaceuticals Limited (ASX:BOT) issued its earnings results on Thursday, February, 28th. The company reported ($0.01) earnings per share (EPS) for the quarter. Botanix Pharmaceuticals had a negative trailing twelve-month return on equity of 18.00% and a negative net margin of 670.20%. What other stocks do shareholders of Botanix Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Botanix Pharmaceuticals investors own include Alphabet (GOOG), Meta Platforms (META), Arafura Rare Earths (ARU), Canopy Growth (CGC), Manning & Napier (MN), (STB.TO) (STB) and (YCB) (YCB). Company Calendar Last Earnings2/28/2019Today5/05/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeASX SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolASX:BOT CIKN/A Webwww.botanixpharma.com Phone+61-8-94820580FaxN/AEmployees11Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)A($0.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-13,870,000.00 Net Margins-670.20% Pretax MarginN/A Return on Equity-18.00% Return on Assets-12.74% Debt Debt-to-Equity RatioN/A Current Ratio22.21 Quick Ratio1.26 Sales & Book Value Annual Sales$2.07 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow1.50 Book ValueA$0.07 per share Price / BookN/AMiscellaneous Outstanding Shares1,810,000,000Free FloatN/AMarket Cap$912.82 million OptionableNot Optionable Beta1.71 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free Report This page (ASX:BOT) was last updated on 5/5/2025 by MarketBeat.com Staff From Our PartnersElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredShocking AI play that’s beats Nvidia by a country mileYou’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is...Timothy Sykes | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredMan who predicted $100K Bitcoin sees a huge run coming for another coin …Sure enough, Bitcoin took off on the exact day Juan said it would. It's up more than 40% since the election...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredMusk's warning signal: Prepare before the cascade beginsWhen Elon Musk triggered his AI layoff plan, most analysts missed what it really meant. Louis Navellier didn’t...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Botanix Pharmaceuticals Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Botanix Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.